| NCT07158437 | Phase 1 Study of SL-325 in Healthy Volunteers | RECRUITING | PHASE1 | 2025-09 | 2026-07 | 2026-07 |
| NCT05483933 | Phase 1b Study of SL-172154 Administered with Combination Agent(s) in Subjects with Ovarian Cancers | COMPLETED | PHASE1 | 2022-08-18 | 2025-02-07 | 2025-02-07 |
| NCT05275439 | Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML | COMPLETED | PHASE1 | 2022-03-17 | 2025-02-06 | 2025-02-06 |
| NCT04502888 | Ph1 Study of SL-172154 Administered Intratumorally in Subjects With Squamous Cell Carcinoma of the Head and Neck or Skin | TERMINATED | PHASE1 | 2020-09-17 | 2022-04-08 | 2022-04-08 |
| NCT04406623 | Phase 1 Study of SL-172154 (SIRPα-Fc-CD40L) in Subjects With Ovarian Cancer | COMPLETED | PHASE1 | 2020-06-29 | 2023-02-02 | 2023-02-02 |
| NCT03894618 | SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas | COMPLETED | PHASE1 | 2019-03-26 | 2023-05-04 | 2023-05-04 |